Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

January 4, 2024

Study Completion Date

March 3, 2024

Conditions
Psoriasis
Interventions
DRUG

GN-037

GN-037

DRUG

Clobetasol 17-propionate

Clobetasol 17-propionate

DRUG

Placebo

Placebo

Trial Locations (18)

34786

Istanbul University Cerrahpasa Faculty of Medicine, Istanbul

38110

Erciyes University Faculty of Medicine, Kayseri

Unknown

Ankara Etlik City Hospital, Ankara

Balıkesir University Faculty of Medicine, Balıkesir

Uludag University Faculty of Medicine, Bursa

Pamukkale University Faculty of Medicine, Denizli

Ataturk University Research Hospital, Erzurum

Basaksehir Cam and Sakura City Hospital, Istanbul

Bezmialem Vakif University Faculty of Medicine, Istanbul

Haydarpasa Numune Training and Research Hospital, Istanbul

Istanbul Haseki Training and Research Hospital, Istanbul

Istanbul University Istanbul Faculty of Medicine, Istanbul

University of Health Sciences Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul

İzmir Democracy University Buca Seyfi Demirsoy Training And Research Hospital, Izmir

Necmettin Erbakan University Meram Faculty of Medicine, Konya

Mersin University Faculty of Medicine, Mersin

Samsun Ondokuz Mayis University Faculty of Medicine, Samsun

Uşak Training and Research Hospital, Uşak

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Monitor CRO

INDUSTRY

lead

GEN İlaç ve Sağlık Ürünleri A.Ş.

INDUSTRY

NCT05706870 - Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis | Biotech Hunter | Biotech Hunter